Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;6(2):199-211.
doi: 10.1007/s40121-017-0153-2. Epub 2017 Mar 29.

Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A. baumannii: A Review

Jennifer N Lashinsky  1 , Oryan Henig  2 , Jason M Pogue  3   4 , Keith S Kaye  2
Affiliations
Review

Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A. baumannii: A Review

Jennifer N Lashinsky et al. Infect Dis Ther. 2017 Jun.

Abstract

Acinetobacter baumannii can cause life-threatening nosocomial infections associated with high rates of morbidity and mortality. In recent years, the increasing number of infections due to extensively drug-resistant Acinetobacter with limited treatment options has resulted in a need for additional therapeutic agents, and a renaissance of older, neglected antimicrobials. This has led to an increased interest in the use of minocycline to treat these infections. Minocycline has been shown to overcome many resistance mechanisms affecting other tetracyclines in A. baumannii, including tigecycline. Additionally, it has favorable pharmacokinetic and pharmacodynamic properties, as well as excellent in vitro activity against drug-resistant A. baumannii. Available data support therapeutic success with minocycline, while ease of dosing with no need for renal or hepatic dose adjustments and improved safety have made it an appealing therapy. This review will focus on the mechanisms of action and resistance to tetracyclines in A. baumannii, the in vitro activity, pharmacokinetic and pharmacodynamic properties of minocycline against A. baumannii, and finally the clinical experience with minocycline for the treatment of invasive infections due to this pathogen.

Keywords: Acinetobacter; Acinetobacter baumannii; Carbapenem resistance; Extensively drug-resistant; Minocycline; Multidrug-resistant; Tetracyclines.

PubMed Disclaimer

References

    1. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006;55(Pt 12):1619–1629. doi: 10.1099/jmm.0.46747-0. - DOI - PubMed
    1. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care. 2006;10(2):R48. doi: 10.1186/cc4869. - DOI - PMC - PubMed
    1. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977–2000. Infect Control Hosp Epidemiol. 2003;24(4):284–295. doi: 10.1086/502205. - DOI - PubMed
    1. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5(12):939–951. doi: 10.1038/nrmicro1789. - DOI - PubMed
    1. Centers for Disease Control and Prevention. Tracking CRE Infections. 2013. http://www.cdc.gov/hai/organisms/cre/TrackingCRE.html. Accessed Oct 2016.